摘要
目的 探讨胸腔内联合灌注重组改构的人肿瘤坏死因子（recombinant mutant human tumor necrosis factor, rmhTNF）和博莱霉素治疗恶性胸腔积液的临床疗效及安全性.方法 经病理确诊的恶性胸腔积液60例, 胸腔置管引流术排尽胸液后 ,随机分为对照组（A组,30例） 在胸腔内灌注博莱霉素60mg,治疗组（B组,30例） 在胸腔内灌注rmhTNF 1 500万U ＋ 博莱霉素60mg,观察疗效及不良反应.结果 A组完全缓解12例,部分缓解9例,无效9例,总有效率70.0%;B组完全缓解19例, 部分缓解9例,无效2例,总有效率93.3%,联合用药组治疗效果明显提高（χ2=5.45,P＜0.05）,2组患者发热、胸痛等不良反应差异无统计学意义（P＞0.05）.但联合用药对患者的生存率无明显影响（P＞0.05）.结论 rmhTNF联合博莱霉素胸腔注射是一种有效、不良反应小、可耐受的疗法,可提高患者的总有效率.
Objective To approach the clinical curative effect and safety of recombinant mutant human tumor necrosis factor（rmhTNF） combined with bleomycin regimens in the treatment of malignant pleural effusion. Methods Sixty cases with malignant pleural effusion were randomly divided into 2 groups. Single - agent bleomycin 60 mg was infused into pleural cavity in group A, and rmhTNF 1 500 million IU and bleomycin 60 mg were infused into pleural cavity in group B. The curative effect, adverse reaction and survival rate were observed. Results In group A, 12 cases complete remission, 9 cases partial remission, the total effective rate was 70.0%. In group B, complete remission 19 cases, partial remission 9 cases, the total effective rate was 93.3%, there was significant difference between the two groups （ P 〈 0. 05 ）. The major toxicities were fever, pleuritic pain, which could be relieved by reasonable treatment for the symptoms, there was no significant difference between the two groups in survival rate （ P 〉 0. 05） . Conclusion The rmhTNF combined with bleomycin regimen is an effective and well -tolerated treatment in patients with malignant pleural effusion.
出处
《河北医科大学学报》
CAS
2010年第7期765-767,共3页
Journal of Hebei Medical University
基金
河北省普通高等学校强势特色学科肿瘤学建设经费资助项目
关键词
胸腔积液
恶性
肿瘤坏死因子类
注射
pleural effusion, malignant
tumor necrosis factors
injections
作者简介
[作者简介]王伟（1973-），男，河北成安人，河北省成安县医院主治医师，医学学士，从事外科疾病诊治研究。
通讯作者。E-mail：xwkwr@yahoo．com．cn
